Skip to main content
. Author manuscript; available in PMC: 2020 Mar 9.
Published in final edited form as: Cell Rep. 2019 Mar 12;26(11):3061–3075.e6. doi: 10.1016/j.celrep.2019.02.032

Figure 6. The Effect of ALDH Inhibition on Tumor Stemness.

Figure 6.

(A) (i) Cell counts of SKOv3 cells over time after treatment with 1 μg/mL cisplatin alone or in combination with ALDH inhibitors. (ii) Synergy factor calculations upon treatment of primary ovarian high grade serous (HGS) samples in spheres (Pt152, Pt259, and Pt224) and breast cancer cell lines (HCC3153, HCC1937, HCC1395, and HCC1569).

(B) Surviving fraction after radiation of FACS-isolated CD133+/− A2780 (i) and ALDH+/− SKOv3 (ii) cells after DMSO or 673A treatment and subsequent radiation, and table of radiation-enhancement ratios (iii).

(C) Sphere formation capacity in primary HGS cells with 673A.

(D) Tumor growth (i) and tumor initiation capacity (ii) of 5,000 FACS-sorted viable (annexin-V−/PI−) cells after single-agent and combined therapy with cisplatin and ALDH inhibitors. Number of established tumors was evaluated 3 months following cell injection.

Error bars represent SDs; n = 3 independent experiments with at least triplicate assays. Data are presented as mean ± SD with *p < 0.05, **p < 0.01, and ***p < 0.005.